ClinicaliQ Trial Snapshot
- Randomized Study in Children and Adolescents With Migraine: Acute Treatment — Recruiting • Phase III • NCT04649242.
- Researchers tested whether a new migraine drug (BHV-3000) works better than placebo for treating severe migraines in young people.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents. Conditions: Pediatric Migraine Interventions: Rimegepant/BHV3000, Matching placebo Lead Sponsor: Pfizer Planned Enrollment: 2100 participants